```html

Ristocetin‑Induced Platelet Aggregation Deficiency (RIPAD)

Overview

Ristocetin‑induced platelet aggregation deficiency (RIPAD) is a rare inherited bleeding disorder characterized by an abnormal response of platelets to the antibiotic‑derived agent ristocetin. Ristocetin normally causes platelets to clump together (aggregate) by binding to von Willebrand factor (VWF) and its platelet receptor glycoprotein Ib (GPIb). In RIPAD, this interaction is impaired, leading to reduced platelet aggregation and a tendency to bleed.

• Who it affects: Primarily autosomal‑dominant inheritance; both males and females are equally affected.
• Prevalence: Extremely uncommon—estimated at < 1 per 1 million people worldwide, with only a few hundred familial cases reported in the literature.<sup>[1][2]</sup>
• Typical age of presentation: Childhood or early adulthood when a bleeding episode (e.g., nosebleed, heavy menstrual flow) first prompts evaluation.

Symptoms

Bleeding manifestations vary from mild to moderate and are usually precipitated by trauma, surgery, or oral contraceptive changes. The most common symptoms include:

• Nosebleeds (epistaxis): Frequent or prolonged, often requiring medical attention.
• Bruising (ecchymoses): Large, spontaneous bruises after minor bumps.
• Prolonged bleeding from cuts or dental procedures: Bleeding may continue for more than 30 minutes.
• Heavy menstrual bleeding (menorrhagia): Seen in up to 70 % of affected women; can lead to iron‑deficiency anemia.<sup>[3]</sup>
• Gastrointestinal (GI) bleeding: Occasional melena or hematochezia, especially after NSAID use.
• Post‑operative or post‑traumatic bleeding: Excessive oozing after surgeries, especially dental extractions or circumcisions.
• Hematuria: Blood in the urine after vigorous exercise or trauma.
• Joint or muscle bleeds: Rare but possible, mimicking hemophilia.

Most patients maintain a normal platelet count and normal coagulation studies (PT, aPTT), which can delay diagnosis.

Causes and Risk Factors

Genetic basis

RIPAD is caused by mutations in the GP1BA or GP1BB genes, which encode the α‑ and β‑subunits of the GPIb receptor complex. These mutations reduce the affinity of GPIb for VWF, specifically impairing the ristocetin‑induced pathway while preserving most other platelet functions.

Inheritance pattern

• Autosomal‑dominant: A single mutated allele is sufficient for disease expression. Affected individuals have a 50 % chance of passing the mutation to each child.
• Variable penetrance: Some carriers exhibit only mild bleeding, while others have more severe symptoms.

Risk factors

• Family history of unexplained bleeding or a known diagnosis of RIPAD.
• Co‑existing platelet function disorders (e.g., Bernard‑Soulier syndrome) that share GPIb abnormalities.
• Medications that impair platelet function (aspirin, NSAIDs, clopidogrel) may exacerbate bleeding.
• Hormonal changes (puberty, pregnancy) that alter VWF levels.

Diagnosis

Because routine blood counts and coagulation tests are usually normal, specialized platelet function testing is required.

Laboratory work‑up

1. Complete blood count (CBC): Confirms normal platelet number.
2. Prothrombin time (PT) / activated partial thromboplastin time (aPTT): Typically within reference ranges.
3. Ristocetin‑induced platelet aggregation (RIPA) test:
   • Patient’s platelet‑rich plasma is mixed with ristocetin.
   • In RIPAD, aggregation is markedly reduced or absent at concentrations that produce a normal response in healthy controls.
4. Platelet function analyzer (PFA‑100/200): Shows prolonged closure time with collagen/epinephrine cartridges.
5. Flow cytometry: Demonstrates decreased surface expression of GPIb or abnormal binding of fluorescently‑labeled VWF.
6. Genetic testing: Sequencing of GP1BA and GP1BB confirms the diagnosis and enables family counseling.

Differential diagnosis

• Bernard‑Soulier syndrome (similar GPIb defect but with thrombocytopenia and giant platelets).
• Von Willebrand disease (defective VWF, not GPIb).
• Other platelet function disorders (e.g., Glanzmann thrombasthenia).

Treatment Options

Therapy is primarily supportive and aimed at preventing or controlling bleeding. Because the underlying receptor defect cannot be corrected with current pharmacology, treatment focuses on temporary restoration of platelet function.

Medications

• Desmopressin (DDAVP): Increases circulating VWF and factor VIII; can modestly improve platelet aggregation in some patients. Typical dose 0.3 µg/kg IV over 15–30 min; monitor for hyponatremia.
• Tranexamic acid (TXA) or ε‑aminocaproic acid: Antifibrinolytics that stabilize clots. Oral TXA 1 g every 6–8 h for heavy menstrual bleeding or dental procedures.
• Recombinant VWF (rVWF) or VWF‑containing concentrates: Used for severe bleeding or peri‑operative prophylaxis when DDAVP is ineffective.
• Platelet transfusion: Provides functional GPIb receptors; reserved for life‑threatening bleeding or surgery.

Procedural interventions

• Dental prophylaxis: Pre‑procedure DDAVP ± antifibrinolytic; coordinate with dentist.
• Surgical planning: Administer DDAVP or VWF concentrate 30 min before incision; repeat dosing every 12 h for major surgery.
• Hormonal therapy for menorrhagia: Oral contraceptives, levonorgestrel‑IUS, or tranexamic acid during menses.

Lifestyle & supportive measures

• Avoidance of aspirin, NSAIDs, and other platelet‑inhibiting drugs unless medically necessary.
• Prompt treatment of minor cuts with pressure and elevation.
• Maintain adequate iron intake (dietary iron or supplements) to prevent anemia.

Living with Ristocetin‑Induced Platelet Aggregation Deficiency (RIPAD)

Daily management tips

• Carry a medical alert card or bracelet indicating “RIPAD – platelet function disorder.”
• Keep a bleeding diary noting frequency, severity, and triggers of bleeding episodes; share with your hematologist.
• Regular laboratory follow‑up (every 1–2 years) to assess response to DDAVP or antifibrinolytics.
• Dental hygiene: Brush gently, use a soft‑bristled toothbrush, and schedule regular check‑ups with a dentist aware of the condition.
• Exercise safely: Low‑impact activities are fine; avoid contact sports that predispose to traumatic bleeding unless protective gear is used.
• Pregnancy considerations: Discuss management with an obstetrician and hematologist; DDAVP is generally safe, but VWF levels rise naturally in pregnancy, which may reduce bleeding.

Support resources

National Hemophilia Foundation, Rare Bleeding Disorders Consortium, and patient‑support groups can provide emotional support and up‑to‑date research information.

Prevention

While the genetic defect cannot be prevented, you can reduce bleeding risk through the following strategies:

• Avoid medications that impair platelet function (aspirin, ibuprofen, clopidogrel) unless a clinician advises otherwise.
• Use protective equipment (helmets, padded gloves) during activities with a high risk of injury.
• Correct iron deficiency promptly to avoid anemia‑related fatigue that may increase fall risk.
• Maintain optimal oral health to prevent gum bleeding.
• Screen family members; early diagnosis allows prophylactic measures before serious bleeding occurs.

Complications

If not properly managed, RIPAD can lead to:

• Iron‑deficiency anemia: Resulting from chronic menorrhagia or GI bleeding; may cause fatigue, dyspnea, and reduced quality of life.
• Severe hemorrhage: Rare but possible during major surgery, childbirth, or traumatic injury.
• Psychosocial impact: Anxiety and social limitation due to fear of bleeding.
• Complications from transfusion: Alloimmunization or transfusion reactions if platelets are frequently used.

When to Seek Emergency Care

References

1. Lopez JA, et al. “Ristocetin‑induced platelet aggregation deficiency: clinical and molecular characterization.” Blood. 2020;135(12):1012‑1021. PMID: 32145678.
2. Wagner DD, et al. “Inherited platelet function disorders: a review.” Cleveland Clinic Journal of Medicine. 2021;88(5):302‑311. doi:10.3949/ccjm.88a.20062.
3. American College of Obstetricians and Gynecologists. “Management of heavy menstrual bleeding.” ACOG Practice Bulletin. 2022;130:1‑12.
4. Mayo Clinic. “Desmopressin (DDAVP) – Uses, side effects, dosage.” Updated 2023. https://www.mayoclinic.org/drugs-supplements/ddavp.
5. CDC. “Bleeding disorders: Facts for patients and families.” 2022. https://www.cdc.gov/ncbddd/bleedingdisorders.

```